Metabolon Receives CLIA Certificate of Registration

The CLIA registration allows Metabolon’s clinical laboratory to perform high-complexity tests on patient samples. Later this year, the company plans to launch tests for insulin resistance and urological cancers based upon biochemical biomarkers the company discovered using its proprietary metabolomic profiling technology platform.

John Ryals, Metabolon’s president and chief executive officer said, “CLIA certification is an important step in our strategy to derive further economic value from our sophisticated approach to biomarker discovery while advancing our plans to fulfill the promise of personalized medicine.”